The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

Eosinophilic gastroenteritis (EGE) is characterized by dense eosinophilic inflammation of one or several digestive tract sections. The symptoms include abdominal pain, weight loss, vomiting and ...

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Embryonic stem cells are pluripotent cells isolated from the inner cell mass of a blastocyst, the early mammalian embryo that implants into the uterus. Embryonic stem cells self-renew by dividing ...

In this Tools of the Trade article, Wang and Cheng (Deng Lab) describe an improved protocol for the generation of human pluripotent stem cells by chemical reprogramming based on the targeting of ...

A low red blood cell (RBC) count increases the risk of anemia. Ways to boost RBCs include eating foods that contain iron, vitamins B12 and B9, vitamin C, vitamin A, and copper. Increasing exercise ...

At its third attempt, Mesoblast has secured FDA approval for Ryoncil as a treatment for children with graft-versus-host disease, the first-ever approval for a mesenchymal stromal cell (MSC ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) with ...